Skip to main content
Premium Trial:

Request an Annual Quote

Decode Licenses Pharsight s Drug-Modeling Software

NEW YORK, Feb. 6 (GenomeWeb) - Pharsight announced today that it has signed a licensing agreement with Decode Genetics for its drug model explorer software.


No financial details were provided.


Pharsight is a Mountain View, Calif. -based provider of drug-discovery modeling tools. The DMX software platform enables users to build predictive models of the efficacy, safety, and other performance attributes of new drugs.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.